These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36469635)

  • 1. Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
    Cesaroni V; Blandini F; Cerri S
    Expert Opin Ther Targets; 2022 Oct; 26(10):837-851. PubMed ID: 36469635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
    Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
    AlShimemeri S; Fox SH; Visanji NP
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):131-144. PubMed ID: 32366130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
    Chen X; Wang Y; Wu H; Cheng C; Le W
    Neurol Sci; 2020 Aug; 41(8):2055-2065. PubMed ID: 32185625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Fidalgo C; Ko WK; Tronci E; Li Q; Stancampiano R; Chuan Q; Bezard E; Carta M
    Neuroscience; 2015 Jul; 298():389-96. PubMed ID: 25907446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
    Dashtipour K; Tafreshi AR; Pahwa R; Lyons KE
    Expert Rev Neurother; 2019 Apr; 19(4):293-299. PubMed ID: 30892103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
    Tronci E; Francardo V
    J Neural Transm (Vienna); 2018 Aug; 125(8):1137-1144. PubMed ID: 29242978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
    Kwon DK; Kwatra M; Wang J; Ko HS
    Cells; 2022 Nov; 11(23):. PubMed ID: 36496996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into pathogenesis of l-DOPA-induced dyskinesia.
    Zheng C; Zhang F
    Neurotoxicology; 2021 Sep; 86():104-113. PubMed ID: 34331976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
    Schaeffer E; Pilotto A; Berg D
    CNS Drugs; 2014 Dec; 28(12):1155-84. PubMed ID: 25342080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
    Bastide MF; Meissner WG; Picconi B; Fasano S; Fernagut PO; Feyder M; Francardo V; Alcacer C; Ding Y; Brambilla R; Fisone G; Jon Stoessl A; Bourdenx M; Engeln M; Navailles S; De Deurwaerdère P; Ko WK; Simola N; Morelli M; Groc L; Rodriguez MC; Gurevich EV; Quik M; Morari M; Mellone M; Gardoni F; Tronci E; Guehl D; Tison F; Crossman AR; Kang UJ; Steece-Collier K; Fox S; Carta M; Angela Cenci M; Bézard E
    Prog Neurobiol; 2015 Sep; 132():96-168. PubMed ID: 26209473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.